Perspectives of healthcare professionals on training for quantitative G6PD testing during implementation of tafenoquine in Brazil (QualiTRuST Study)

• Published in: PLoS neglected tropical diseases 2024-06, Vol.18 (6), p.e0012197
• Main Authors: Santos, Alicia, Brito, Marcelo, Silva, Evellyn, Rocha, Felipe, Oliveira, Ana, Dávila, Rafaela, Gama, Hiran, Albuquerque, Jéssica, Paiva, Mena, Baía-Silva, Djane, Sampaio, Vanderson, Balieiro, Patrícia, Rufatto, Rosilene, Grewal Daumerie, Penny, Peterka, Cássio, Edilson Lima, Jr, Francisco, Monteiro, Wuelton, Arcanjo, Ana, Silva, Ricardo, Batista Pereira, Dhelio, Lacerda, Marcus, Murta, Felipe
• Format: Article
• Language: English
• Subjects: Adult; Algorithms; Aminoquinolines; Aminoquinolines - therapeutic use; Anniversaries; Antimalarials - therapeutic use; Beliefs, opinions and attitudes; Biology and Life Sciences; Biosensors; Blood; Brazil; Breastfeeding & lactation; Care and treatment; Chloroquine; Dosage and administration; Engineering and Technology; Enzymes; Ethics; Female; Glucose 6 phosphate dehydrogenase; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency - diagnosis; Grants; Haemolysis; Health care; Health Personnel - education; Hemoglobin; Human diseases; Humans; Malaria; Malaria, Vivax - drug therapy; Malaria, Vivax - prevention & control; Male; Medical examination; Medical personnel; Medicine and Health Sciences; Patient safety; People and places; Pharmacovigilance; Phosphates; Plasmodium vivax - drug effects; Primary care; Qualitative research; Random sampling; Social Sciences; Tafenoquine; Training; Tropical diseases; Vector-borne diseases
• ISSN: 1935-2727; 1935-2735; 1935-2735
• DOI: 10.1371/journal.pntd.0012197

Effective radical cure of Plasmodium vivax malaria is essential for malaria elimination in Brazil. P. vivax radical cure requires administration of a schizonticide, such as chloroquine, plus an 8-aminoquinoline. However, 8-aminoquinolines cause hemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, requiring prior screening to exclude those at risk. Brazil is pioneering the implementation of tafenoquine, a single-dose 8-aminoquinoline indicated for P. vivax patients with >70% of normal G6PD activity. Tafenoquine implementation in Manaus and Porto Velho, two municipalities located in the western Brazilian Amazon, included comprehensive training of healthcare professionals (HCPs) on point-of-care quantitative G6PD testing and a new treatment algorithm for P. vivax radical cure incorporating tafenoquine. Training was initially provided to higher-level facilities (phase one) and later adapted for primary care units (phase two). This study analyzed HCP experiences during training and implementation and identified barriers and facilitators. In-depth interviews and focus discussion groups were conducted 30 days after each training for a purposive random sample of 115 HCPs. Thematic analysis was employed using MAXQDA software, analyzing data through inductive and deductive coding. Analysis showed that following the initial training for higher-level facilities, some HCPs did not feel confident performing quantitative G6PD testing and prescribing the tafenoquine regimen. Modifications to the training in phase two resulted in an improvement in understanding the implementation process of the G6PD test and tafenoquine, as well as in the knowledge acquired by HCPs. Additionally, knowledge gaps were addressed through in situ training, peer communication via a messaging app, and educational materials. Training supported effective deployment of the new tools in Manaus and Porto Velho and increased awareness of the need for pharmacovigilance. A training approach for nationwide implementation of these tools was devised. Implementing quantitative G6PD testing and tafenoquine represents a significant shift in P. vivax malaria case management. Consistent engagement with HCPs is needed to overcome challenges in fully integrating these tools within the Brazilian health system.